Uncategorized

One Antibody, Fewer Scientific Surprises

Published

2 weeks ago

June 1, 2026

Sponsored content brought to you by

In biomedical research, promising programs rarely collapse for lack of scientific ambition. More often, they collapse under the weight of inconsistency. One assay produces compelling results, the next model delivers confusion, and suddenly, researchers are left wondering whether the biology changed or whether the tools did.

That uncertainty sits at the heart of translational continuity, a concept gaining increased attention as drug-discovery pipelines become more complex and expensive. According to Cody Spencer, PhD, Director of Scientific Affairs at Bio X Cell, maintaining continuity across experimental systems is less about rigidly replicating conditions and more about reducing unnecessary variability.

“I define translational continuity as the ability to study the same underlying biology as you move from early discovery into more complex preclinical models without introducing unnecessary variability,” Spencer explains.

In practice, translational continuity means researchers can move from in vitro assays to organoids to in vivo mouse models while remaining confident that their findings reflect real biological phenomena, not artifacts created by inconsistent reagents or shifting methodologies. That distinction matters more than many researchers realize.

The greatest threat to continuity, Spencer argues, is often surprisingly mundane: switching antibodies or suppliers midway through a research program. Even antibodies marketed against the same target protein can behave differently depending on clone selection, sequence, production methods, formulation, or purification standards. When an antibody’s functional profile—whether blocking, agonistic, or depleting—is well characterized, researchers can select tools aligned with their experimental goals from the start, reducing the need to switch reagents mid-program. “When you switch suppliers, you’re often introducing a new variable without fully realizing it,” Spencer says.

Those differences might seem subtle initially, but they can snowball dramatically in translational studies. Inconsistent potency, altered dose responses, or unintended immune engagement can suddenly emerge even when earlier experiments appeared rock solid. Researchers then face a dangerous interpretive trap: Are they observing a genuine biological effect or merely the consequences of a reagent change? “That’s where you start to see promising early data that doesn’t hold up in more complex models,” Spencer notes.

The consequences extend beyond scientific frustration. Failed translation burns time, funding, and institutional confidence. Entire programs can stall while teams attempt to reconcile conflicting datasets generated by technically different reagents presenting as equivalent tools. For companies operating in high-stakes therapeutic areas like immuno-oncology, autoimmune disease, and inflammatory disorders, that level of ambiguity can become extraordinarily expensive.

The formulation of antibodies also plays a surprisingly large role in reproducibility, particularly in vivo. Preservatives, endotoxin contamination, and formulation inconsistencies can introduce unintended biological effects that distort experimental outcomes. “For in vivo studies, antibodies need to have ultra-low endotoxin levels and be free of preservatives to avoid introducing unintended biological effects,” Spencer explains.

This emphasis on reproducibility has reinforced the case for recombinant antibodies, which are derived from defined sequences rather than traditional hybridoma methods. Recombinant production offers stronger lot-to-lot consistency and allows researchers to better control host species, isotype selection, and Fc functionality.

That predictability becomes even more critical as antibody engineering grows more sophisticated. Bispecific antibodies, for example, can engage two targets simultaneously, enabling researchers to model increasingly complex biological interactions. But those advanced formats also amplify the risks associated with inconsistency. “Small changes can significantly impact activity,” Spencer warns.

Ultimately, translational continuity is about preserving confidence. In an era where reproducibility concerns continue to challenge biomedical science, researchers are increasingly recognizing that experimental reliability depends not only on biological insight but also on the consistency of the tools used to generate it. “When translational continuity is strong, the data become much easier to interpret,” Spencer says. “If the biology is real, it should carry across systems.”

Learn more bioxcell.com.

The post One Antibody, Fewer Scientific Surprises appeared first on GEN – Genetic Engineering and Biotechnology News.

Uncategorized

Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks

Published

1 hour ago

June 12, 2026

Temp User

Strong science, lower costs and growing capital networks are putting Spain and Portugal on the biotech investment map, even as structural bottlenecks persist, according to two investors.

Uncategorized

Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins

Published

6 hours ago

June 12, 2026

Temp User

You know when you are at the eye doctor getting an updated prescription, and suddenly the world snaps into sharper focus? Physicists at the University of California (UC), Berkeley, have now done something similar for electron microscopy. By introducing phase contrast into a cryo‑electron microscope, they have delivered dramatically sharper images of some of biology’s smallest and most elusive proteins.

The advance comes from a new laser phase plate (LPP), described in the paper “Laser phase plate improves structure determination of small proteins by cryo‑EM,” which was published recently in Science. Led by physicist Holger Mueller, PhD, of UC Berkeley and Lawrence Berkeley National Laboratory, the team demonstrated that a laser‑driven phase plate can overcome one of cryo‑EM’s most persistent limitations: poor contrast for small proteins.

Cryo-EM images of two proteins, apoferritin and hemoglobin, taken without and with a laser phase plate. The images are analyzed in a computer to produce detailed 3D structures of the proteins. [Holger Müller, Jessie Zhang/UC Berkeley]

Cryo‑EM has transformed structural biology over the past decade, earning a Nobel Prize in 2017 for enabling high‑resolution structures without crystallization. But despite its impact, the technique still struggles with proteins below ~70 kilodaltons—a size range that includes about 90% of the human proteome. “Because of signal-to-noise limitations, the majority of human and animal proteins are too small to be analyzed by these methods [cryo-EM and cryoelectron tomography]. The increase in signal-to-noise ratio provided by this laser phase plate is expected to overcome these important limitations.”

The new LPP begins to address that problem. The LPP uses an intense, continuous‑wave laser to shift the phase of the electron beam itself. This produces true phase contrast without dimming or destabilizing the beam. Mueller described the laser focus as “75 kilowatts focused to a few microns… That’s more powerful than what you use for welding. It has more power than a military laser. It builds up the brightest continuous laser focus ever.”

Installed in a custom Thermo Fisher Titan Krios, the LPP immediately improved the clarity and resolvability of small proteins, including hemoglobin, which sits at the lower limit of what today’s cryo‑EM instruments can handle. As the authors wrote in the abstract: “Here, we show that the laser phase plate (LPP)… enhances the resolution in single-particle reconstruction of small proteins by improving specimen-motion correction, recovery of information from the early frames, as well as particle visualization, 3D classification, and alignment.”

phase plate cover Cryo-EM — A laser (purple) is powerfully amplified by highly polished mirrors and focused on the electron beam (blue) to shift its phase and increase the cryo-EM microscope’s contrast, allowing biologists to image smaller proteins and the crowded structures inside cells. [Sayo Studio]

These improvements were achieved using standard defocus ranges and reconstruction workflows. “For the most challenging cases—small particles, bad specimens—the laser produces a very considerable advantage,” Mueller said.

The impact extends beyond single‑particle analysis. Cryo‑electron tomography (cryo‑ET), which assembles multiple angular views of a molecule or protein into a three-dimensional image, stands to benefit even more. “With cryo-ET, we’re looking at small, very complicated cellular material that’s incredibly crowded inside the cell,” said Bridget Carragher, PhD, founding technical director of imaging at Biohub. “It’s like a forest of trees, and you’re trying to find one leaf on one tree in there. Cryo-ET needs a dramatic step forward in contrast, so we can start to see what’s going on inside the cell. That’s what the laser phase plate promises to give us.”

Biohub is developing a dual‑laser version of the system, designed to reduce component wear and minimize aberrations. Meanwhile, Mueller’s team is pushing toward imaging proteins as small as 17 kilodaltons, a threshold that would open access to vast regions of the human proteome previously invisible to cryo‑EM.

“This technology is a step function change for biology,” said Stephani Otte, PhD, Biohub’s vice president of imaging science. “What was once invisible will become visible—and that changes everything about how we understand disease.”

“The bottom line is, if you have a large protein and a really good sample—a fresh one or one frozen without bubbles, for example—you may not need the phase plate to get a single, high-quality image. But for a small protein and a bad sample, laser-on is best,” Mueller said. “This could fill an enormous gap in our knowledge of protein structures that can’t be crystallized or are too small for today’s cryo-EM. And it will be revolutionary for cryo-ET.”

The post Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins appeared first on GEN – Genetic Engineering and Biotechnology News.

Uncategorized

STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America

Updated June 11, 2026

WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.

“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.

Continue to STAT+ to read the full story…

Published

8 hours ago

June 12, 2026

Temp User